» Articles » PMID: 36451110

Sorafenib Inhibits Interferon Production by Plasmacytoid Dendritic Cells in Hepatocellular Carcinoma

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Nov 30
PMID 36451110
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sorafenib is a multi-kinase inhibitor that shows antitumor activity in advanced hepatocellular carcinoma. Sorafenib exerts a regulatory effect on immune cells, including T cells, natural killer cells and dendritic cells. Studies have shown that plasmacytoid dendritic cells (pDCs) are functionally impaired in cancer tissues or produce low type I interferon alpha (IFNα) in cancer microenvironments. However, the effects of sorafenib on the function of pDCs have not been evaluated in detail.

Methods: Normal and patient PBMCs were stimulated with CpG-A to evaluate IFNα production with Flow cytometry and ELISA.

Result: We analyzed the production of IFNα by PBMCs in patients with advanced HCC under sorafenib treatment. We found that sorafenib-treated HCC patients produced less IFNα than untreated patients. Furthermore, we demonstrated that sorafenib suppressed the production of IFNα by PBMCs or pDCs from heathy donors in a concentration-dependent manner.

Conclusion: Sorafenib suppressed pDCs function. Given that sorafenib is a currently recommended targeted therapeutic agent against cancer, our results suggest that its immunosuppressive effect on pDCs should be considered during treatment.

Citing Articles

The Multifaceted Functionality of Plasmacytoid Dendritic Cells in Gastrointestinal Cancers: A Potential Therapeutic Target?.

Hansen F, David P, Weber G Cancers (Basel). 2024; 16(12).

PMID: 38927922 PMC: 11201847. DOI: 10.3390/cancers16122216.


Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer.

Xie Y, Wu H, He Y, Liu L, Huang I, Zhou L Cell Death Dis. 2024; 15(2):110.

PMID: 38310091 PMC: 10838288. DOI: 10.1038/s41419-024-06493-0.

References
1.
Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P . Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005; 65(12):5020-6. DOI: 10.1158/0008-5472.CAN-04-4043. View

2.
Takata Y, Nakamoto Y, Nakada A, Terashima T, Arihara F, Kitahara M . Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Lett. 2011; 307(2):165-73. DOI: 10.1016/j.canlet.2011.03.029. View

3.
Liu Y . IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306. DOI: 10.1146/annurev.immunol.23.021704.115633. View

4.
Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G . Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res. 2004; 10(21):7260-9. DOI: 10.1158/1078-0432.CCR-04-0872. View

5.
Treilleux I, Blay J, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla J . Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004; 10(22):7466-74. DOI: 10.1158/1078-0432.CCR-04-0684. View